News

The new solution will support the new XEVMPD submission standard, which goes into effect on 2 July 2012. The new XEVMPD regulation mandates that life sciences firms use

BioClinica customers will make use of Paragon’s resources to carry large-scale integration of BioClinica’s eClinical solutions across technology partnerships and client implementations. The Paragon partnership unites BioClinica’s OnPoint

The technology eliminates sample preparation steps in addition to the need for front-end gas or liquid chromatography separation. With the AxION DSA system, sample preparation time is now

VistaGen will utilize the licensed technology to develop hematopoietic precursor stem cells from human pluripotent stem cells, to develop drug screening and cell therapy applications for human blood

The patent makes claims in the uses of a urinary Small MBL-associated protein C-terminal fragment (sMAP) in the diagnosis of ovarian cancer, ovarian cancer monitoring, and patient management.

The addition of the Qualicaps FS3 unit to the company’s manufacturing capabilities is expected to increase overall efficiency at the Phase 2 production scale. The unit, which is

As per the agreement, Merck, through a subsidiary, will gain worldwide rights to develop and commercialize vintafolide. Endocyte will receive a $120m upfront payment and is eligible for

MORAb-004 is a monoclonal antibody that binds to endosialin/tumor endothelial marker-1 (TEM-1). The randomized, double-blind study is designed to assess the efficacy and safety of single agent MORAb-004

In pursuance of the memorandum of understanding signed with the Government of Gujarat in 2009, the company had invested over Rs5bn ($100m) to build a SEZ. Jubilant Life